Tel: +44 (0) 1904 406082
Abingdon Health launches AppDx Smartphone reader technology
Learn more
What are the common myths about lateral flow devices?
Read More
Two Successful Immunoassay formats
Read More

Rapid diagnostics, in essence, brings testing away from the laboratory and closer to the patient, in the case of clinical diagnostics or veterinary diagnostics, or quite literally into the field, in the case of agricultural diagnostics. One key benefit of rapid testing is faster decision making which leads to earlier diagnosis, monitoring and treatment. Abingdon Health’s focus on rapid diagnostics is lateral flow testing, an established fast-growing segment of the market.

Lateral flow devices, commonly referred to as LFDs, use immunoassay technology via a combination of antibodies, nitrocellulose membranes and coloured nanoparticles in order to produce visually interpreted results. In addition to using antibodies; aptamers, affirmers or other novel reagents can be incorporated. Lateral flow devices can also be combined with reader technology to produce rapid fully quantitative results.

Why are lateral flow rapid tests important?

This image shows the interior of a lateral flow immunoassay.According to MarketsandMarkets (August 2017), the global lateral flow assay market is projected to reach USD 8.24 Billion by 2022, up from USD 5.14 Billion in 2016, growing at a Compound Annual Growth Rate (CAGR) of 8.2%. The market drivers derive from an ageing population, greater incidences of disease, increased use of home-based tests, a desire for rapid testing across multiple sectors and a focus on decentralised testing.

Building on decades of research we have better insight into the causative agents of human, animal and plant disease, and the impact of substances on the environment and health. The ability to identify the biomarkers linked to these disease or environmental conditions means we can predict, monitor or diagnose more effectively and put in place treatments or preventative measures.

As this knowledge is shared between organisations and the public there is an increasing interest in early stage detection, on-going monitoring, and for real-time results. This is where a lateral flow rapid test comes into its own by offering a flexible, cost-effective and time-saving solution.

Lateral flow tests incorporate quick, easy-to-use protocols and can be used with minimal training. By providing a real-time result, time is saved compared to a laboratory test or is a helpful tool to direct further laboratory testing. Because of their ease of use and portability, lateral flow tests are used in multiple industries and testing scenarios from the home or field, to emergency rooms and ambulances.

An example of the importance of rapid tests is demonstrated by UNICEF’s increased procurement of malaria rapid diagnostic tests (mRDTs). In 2008 UNICEF bought 3.8 million tests with this figure increasing to approximately 13 million in 2015.

Efficient diagnosis

Although lateral flow rapid tests are simple to use, the science behind these assays is complex.  Assay development follows a stage-by-stage process of feasibility, optimisation, before moving to technical transfer and manufacturing.

It takes many years of experience and knowledge as well as the use of efficient lateral flow manufacturing equipment to produce an optimised, robust, rapid test strip suitable for market use.

During assay development, scientists will select the most appropriate raw materials (reagents, membranes, labels and antibodies) and optimise the test depending on sample type and market requirements.

clickable image for more information about AppDx Smatphone lateral flow reader

In addition, the biomarker of interest may be better suited to a particular assay format or label. We explain the pros and cons of each assay type in our article, Lateral flow immunoassay formats.

The quick and user-friendly protocols allow lateral flow assays to save time in a busy doctor or veterinary surgeries, or laboratories. In addition, desktop or Smartphone lateral flow reader technology can aid in the rapid quantitative diagnosis and management of patients where other diagnostic methods may take longer.

Diagnostic scenarios where lateral flow rapid tests can be applied

  • In-the-field pre-screening prior to more time-consuming laboratory analysis
  • Routine testing or rapid diagnosis in a doctors’ or veterinary surgery
  • The confirmation of the presence or absence of a target in remote areas or in agricultural scenarios
  • Quantitative analysis, by clinicians or veterinarians, for the diagnosis and on-going management of a disease
  • Confirmation of concentration levels to assess disease status in high-value crops
  • Quantification of contaminant levels in food and feed

Reader image to represent Abingdon Health's Lateral Flow Reader OEM service

By taking these scenarios into account Abingdon Health has developed qualitative and quantitative products in order to utilise the capabilities of lateral flow assays. In addition, we have developed a large number of diagnostic tests, across many industry sectors, as part of our lateral flow assay and reader contract services.

  • Seralite® – FLC Serum combines lateral flow and reader technology for the quantitative measurement of kappa and lambda immunoglobulin free light chains (FLCs) to aid the diagnosis and management of myeloma patients.
  • PCRD is a nucleic acid lateral flow immunoassay (NALFIA) used post-DNA-amplification, in multiple industry sectors, for rapid nucleic acid detection.
  • Pocket Diagnostic® is a range of lateral flow plant disease tests (targets include Phytophthora spp., Erwinia amylovora, Potato virus Y and Ralstonia solanacearum) designed to help prevent the spread of disease throughout plant stocks, crops, trees and food.

For more information about why lateral flow rapid tests are important please speak to a member of our team on or +44 (0) 1904 406050.

Author image: Malcolm Briggs, Abingdon Health's Sales and Marketing Executive

Contact Malcolm

First published 26th June 2017 (revised 20th November 2018)